158 related articles for article (PubMed ID: 31122098)
1. Does nephrotoxicity develop less frequently when vancomycin is combined with imipenem-cilastatin than with meropenem? A comparative study.
Hakeam HA; AlAnazi L; Mansour R; AlFudail S; AlMarzouq F
Infect Dis (Lond); 2019 Aug; 51(8):578-584. PubMed ID: 31122098
[No Abstract] [Full Text] [Related]
2. Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats.
Nakamura T; Hashimoto Y; Kokuryo T; Inui KI
Pharm Res; 1998 May; 15(5):734-8. PubMed ID: 9619782
[TBL] [Abstract][Full Text] [Related]
3. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
Garau J; Blanquer J; Cobo L; Corcia S; Daguerre M; de Latorre FJ; León C; Del Nogal F; Net A; Rello J
Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
[TBL] [Abstract][Full Text] [Related]
4. Comparative review of imipenem/cilastatin versus meropenem.
Salmon-Rousseau A; Martins C; Blot M; Buisson M; Mahy S; Chavanet P; Piroth L
Med Mal Infect; 2020 Jun; 50(4):316-322. PubMed ID: 32035719
[TBL] [Abstract][Full Text] [Related]
5. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
Shah PM; Heller A; Fuhr HG; Walther F; Halir S; Schaumann R; Böhme A; Jung B; Köhler A; Lips-Schulte C; Stille W
Infection; 1996; 24(6):480-4. PubMed ID: 9007599
[TBL] [Abstract][Full Text] [Related]
6. Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats.
Nakamura T; Kokuryo T; Hashimoto Y; Inui KI
J Pharm Pharmacol; 1999 Feb; 51(2):227-32. PubMed ID: 10217324
[TBL] [Abstract][Full Text] [Related]
7. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
Nichols RL; Smith JW; Geckler RW; Wilson SE
South Med J; 1995 Apr; 88(4):397-404. PubMed ID: 7716590
[TBL] [Abstract][Full Text] [Related]
8. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
Hornik CP; Herring AH; Benjamin DK; Capparelli EV; Kearns GL; van den Anker J; Cohen-Wolkowiez M; Clark RH; Smith PB;
Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776
[TBL] [Abstract][Full Text] [Related]
9. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
[TBL] [Abstract][Full Text] [Related]
10. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus.
Embil JM; Soto NE; Melnick DA
Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293
[TBL] [Abstract][Full Text] [Related]
11. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
[TBL] [Abstract][Full Text] [Related]
12. Flucloxacillin worsens while imipenem-cilastatin protects against vancomycin-induced kidney injury in a translational rat model.
Pais GM; Marianski S; Valdez K; Melicor RP; Liu J; Rohani R; Chang J; Tong SYC; Davis JS; Scheetz MH
Br J Pharmacol; 2024 Mar; 181(5):670-680. PubMed ID: 37696768
[TBL] [Abstract][Full Text] [Related]
13. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
Kuo BI; Fung CP; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
[TBL] [Abstract][Full Text] [Related]
14. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
Geroulanos SJ
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
[TBL] [Abstract][Full Text] [Related]
15. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
[TBL] [Abstract][Full Text] [Related]
16. Paediatric acute kidney injury induced by vancomycin monotherapy versus combined vancomycin and meropenem.
Zhang T; Cheng H; Li Y; Dong YZ; Zhang Y; Cheng XL; Wang AM; Dong YL
J Clin Pharm Ther; 2019 Jun; 44(3):440-446. PubMed ID: 30737860
[TBL] [Abstract][Full Text] [Related]
17. A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem.
Wu Y; Chen K; Shi Z; Wang Q
Curr Pharm Biotechnol; 2014; 15(8):685-90. PubMed ID: 25051950
[TBL] [Abstract][Full Text] [Related]
18. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group.
Hamacher J; Vogel F; Lichey J; Kohl FV; Diwok K; Wendel H; Lode H
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():121-33. PubMed ID: 8543488
[TBL] [Abstract][Full Text] [Related]
19. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
[TBL] [Abstract][Full Text] [Related]
20. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
Colardyn F; Faulkner KL
J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
